SEARCH

SEARCH BY CITATION

References

  • 1
    McFarlane, D. (2007) Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Res. Rev. 6, 54-63.
  • 2
    Schott, H.C. (2002) Pituitary pars intermedia dysfunction: equine Cushing's disease. Vet. Clin. N. Am.: Equine Pract. 18, 237-270.
  • 3
    Schott, H.C. Fun facts about pituitary pars intermedia dysfunction in horses. Proceedings in: Equine endocrinology summit, Charleston SC, USA. 2011.
  • 4
    Dybdal, N.O., Hargreaves, K.M., Madigan, J.E., Gribble, D.H., Kennedy, P.C. and Stabenfeldt, G.H. (1994) Diagnostic testing for pituitary pars-intermedia dysfunction in horses. J. Am. Vet. Med. Ass. 204, 627-632.
  • 5
    Frank, N., Andrews, F.M., Sommardahl, C.S., Eiler, H., Rohrbach, B.W. and Donnell, R.L. (2006) Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses. J. Vet. Intern. Med. 20, 987-993.
  • 6
    Beech, J., Boston, R., Lindborg, S. and Russell, G.E. (2007) Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia. J. Am. Vet. Med. Ass. 231, 417-426.
  • 7
    McFarlane, D., Beech, J. and Cribb, A. (2006) Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. Domest. Anim. Endocrinol. 30, 276-288.
  • 8
    Horowitz, M.L., Neal, L. and Watson, J.L. (2003) Characteristics of plasma adrenocorticotropin, β-endorphin and α-melanocyte stimulating hormone as diagnostic tests for pituitary pars intermedia dysfunction in the horse. J. Vet. Intern. Med. 17, 386.
  • 9
    Couetil, L., Paradis, M.R. and Knoll, J. (1996) Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J. Vet. Intern. Med. 10, 1-6.
  • 10
    Perkins, G.A., Lamb, S., Erb, H.N., Schanbacher, B., Nydam, D.V. and Divers, T.J. (2002) Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet. J. 34, 679-685.
  • 11
    McFarlane, D., Donaldson, M.T., McDonnell, S.M. and Cribb, A.E. (2004) Effects of season and sample handling on measurement of plasma alpha-melanocyte-stimulating hormone concentrations in horses and ponies. Am. J. Vet. Res. 65, 1463-1468.
  • 12
    Donaldson, M.T., McDonnell, S.M., Schanbacher, B.J., Lamb, S.V., Mcfarlane, D. and Beech, J. (2005) Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J. Vet. Intern. Med. 19, 217-222.
  • 13
    Copas, V.E. and Durham, A.E. (2011) Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction. Equine Vet. J. Epub ahead of print; doi: 10.1111/j.2042-3306.2011.00444.x.
  • 14
    van der Kolk, J.H., Heinrichs, M., van Amerongen, J.D., Stooker, R.C., in de Wal, L.J. and van den Ingh, T.S. (2004) Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma. Am. J. Vet. Res. 65, 1701-1707.
  • 15
    McFarlane, D., Miller, L.M., Craig, L.E., Dybdal, N.O., Habecker, P.L., Miller, M.A., Patterson, J.S. and Cribb, A.E. (2005) Agreement in histologic assessments of the pituitary pars intermedia in aged horses. Am. J. Vet. Res. 66, 2055-2059.
  • 16
    Miller, M.A., Pardo, I.D., Jackson, L.P., Moore, G.E. and Sojka, J.E. (2008) Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet. Pathol. 45, 26-38.
  • 17
    McGowan, T.W., Pinchbeck, G.L., Phillips, C., Perkins, N., Hodgson, D.R. and McGowan, C.M. (2010) A survey of aged horses in Queensland, Australia. Part 1: management and preventive health care. Aust. Vet. J. 88, 420-427.
  • 18
    Ruopp, M.D., Perkins, N.J., Whitcomb, B.W. and Schisterman, E.F. (2008) Youden index and optimal cut-point estimated from observations affected by a lower limit of detection. Biom. J. 50, 419-430.
  • 19
    Van der Kolk, J.H., Wensing, T., Kalsbeek, H.C. and Breukink, H.J. (1995) Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domest. Anim. Endocrinol. 12, 35-39.
  • 20
    Hillyer, M.H., Taylor, F.G., Mair, T.S., Murphy, D., Watson, T.D.G. and Love, S. (1992) Diagnosis of hyperadrenocorticism in the horse. Equine Vet. Educ. 4, 131-134.
  • 21
    McGowan, C. (2003) Diagnostic and management protocols for equine Cushing's syndrome. In Pract. 25, 586-592.
  • 22
    Fluss, R., Faraggi, D. and Reiser, B. (2005) Estimation of the Youden Index and its associated cutoff point. Biom. J. 47, 458-472.
  • 23
    Greiner, M., Pfeiffer, D. and Smith, R.D. (2000) Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. Prev. Vet. Med. 45, 23-41.
  • 24
    McFarlane, D., Paradis, M.R., Zimmel, D., Sykes, B., Brorsen, B.W., Sanchez, A. and Vainio, K. (2011) The effect of geographic location, breed, and pituitary dysfunction on seasonal adrenocorticotropin and α-melanocyte-stimulating hormone plasma concentrations in horses. J. Vet. Intern. Med. 25, 872-881.
  • 25
    Lee, Z.Y., Zylstra, R. and Haritou, S.J. (2010) The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses. Vet. J. 185, 58-61.
  • 26
    Petrie, A. and Watson, P. (2006) Additional techniques. In: Statistics for Veterinary and Animal Science, 2nd edn., Wiley-Blackwell, Oxford. pp 191-195.